UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -138.43M | -126.87M | -115.38M | -113.58M | -104.32M |
| Total Depreciation and Amortization | 1.33M | 1.19M | 1.30M | 1.45M | 1.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.20M | 23.99M | 20.96M | 21.34M | 19.83M |
| Change in Net Operating Assets | 6.85M | 4.93M | -3.02M | 5.01M | 558.00K |
| Cash from Operations | -107.06M | -96.77M | -96.14M | -85.78M | -82.30M |
| Capital Expenditure | -339.00K | -295.00K | -236.00K | -240.00K | -171.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.76M | -20.32M | -92.34M | 14.81M | 6.47M |
| Cash from Investing | -60.09M | -20.61M | -92.58M | 14.57M | 6.30M |
| Total Debt Issued | 24.49M | 24.49M | 24.49M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 96.87M | 151.49M | 151.46M | 203.72M | 122.22M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 18.64M | 18.64M | 18.64M | 67.34M | 48.70M |
| Cash from Financing | 140.00M | 194.62M | 194.59M | 271.06M | 170.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.15M | 77.24M | 5.87M | 199.85M | 94.91M |